IPP Bureau

Rockwell study highlights need for highly skilled workforce for life sciences
Rockwell study highlights need for highly skilled workforce for life sciences

By IPP Bureau - September 27, 2024

Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers

Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis
Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis

By IPP Bureau - September 27, 2024

Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism

Alkem denies claims of Pan-D, Clavam 625 batches being substandard quality
Alkem denies claims of Pan-D, Clavam 625 batches being substandard quality

By IPP Bureau - September 27, 2024

The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem

Alembic receives USFDA final approval for Paliperidone ER tablets
Alembic receives USFDA final approval for Paliperidone ER tablets

By IPP Bureau - September 27, 2024

Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia

Briefs: Krsnaa Diagnostics and Anuh Pharma
Briefs: Krsnaa Diagnostics and Anuh Pharma

By IPP Bureau - September 27, 2024

Krsnaa Diagnostics receives LoI from RINPAS for radiology services

USV launches Q rite tablets for treatment of rare aprhythmia in heart patients
USV launches Q rite tablets for treatment of rare aprhythmia in heart patients

By IPP Bureau - September 27, 2024

Quinidine Sulphate helps manage rare irregular heartbeat conditions

Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD

By IPP Bureau - September 27, 2024

Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

By IPP Bureau - September 27, 2024

At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts

Granules India launches 'Breast Health Express' mobile unit
Granules India launches 'Breast Health Express' mobile unit

By IPP Bureau - September 26, 2024

The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need

Biocon Biologics Global to raise funds through senior secured notes
Biocon Biologics Global to raise funds through senior secured notes

By IPP Bureau - September 26, 2024

The Notes shall not be offered or sold in India

Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan
Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan

By IPP Bureau - September 26, 2024

The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg

Pfizer withdraws all lots of sickle cell disease treatment voxelotor
Pfizer withdraws all lots of sickle cell disease treatment voxelotor

By IPP Bureau - September 26, 2024

Pfizer's decision is based on the totality of clinical data

Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022
Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022

By IPP Bureau - September 25, 2024

She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all

Nadda asked NMC to add 75,000 medical seats
Nadda asked NMC to add 75,000 medical seats

By IPP Bureau - September 25, 2024

NMC to continue its efforts to improve and enhance the quality of medical education in the country

Vaishali Pharma plans M&A route to drive growth
Vaishali Pharma plans M&A route to drive growth

By IPP Bureau - September 25, 2024

Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies

Latest Stories

Interviews

Packaging